Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation vs Continuation of IST in Chronic GVHD
NCT03483675Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2018
- Primary completion
- May 2020
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Feasibility of Enrolling Patients at 22.9 months. Started Jun 2018; status: completed.
02
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT03483675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03483675.